- Conditions
- Lumbosacral Radiculopathy
- Interventions
- Clonidine Micropellets, Sham
- Combination Product · Other
- Lead sponsor
- Sollis Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 33
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–352
of 352
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Heart Failure
- Interventions
- Rexlemestrocel-L, Sham Comparator
- Biological · Other
- Lead sponsor
- Mesoblast, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Mesa, Arizona + 45 more
- Conditions
- Geographic Atrophy
- Interventions
- Vonaprument, Sham Administration
- Drug · Other
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 71
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Fullerton, California + 64 more
- Conditions
- Pain, Postoperative
- Interventions
- Local anesthesia at incision site, Sham QL, Sham Local, QL
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Postoperative Ocular Inflammation, Postoperative Ocular Pain
- Interventions
- Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension)
- Procedure · Drug
- Lead sponsor
- Harrow Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Chronic Pancreatitis
- Interventions
- EUS-guided celiac plexus block, Sham procedure
- Procedure
- Lead sponsor
- Orlando Health, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Diabetic Macular Edema
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 48
- States / cities
- La Jolla, California • Redlands, California • Santa Maria, California + 44 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 79
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more
- Conditions
- Non-Proliferative Diabetic Retinopathy
- Interventions
- Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24
- Drug · Other
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Hagerstown, Maryland
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- Ranibizumab, Triamcinolone Acetonide, Sham injection, Focal/grid laser
- Drug · Behavioral · Procedure
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 56
- States / cities
- Artesia, California • Beverly Hills, California • Irvine, California + 46 more
- Conditions
- Diabetic Macular Edema
- Interventions
- IVT aflibercept, Sham SC, SC CLS-TA
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 25 more
- Conditions
- Mitral Regurgitation, Mitral Valve Insufficiency, Mitral Valve Prolapse
- Interventions
- Erector spinae plane catheter with 0.5% Ropivacaine, Erector spinae plane catheter with saline
- Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Geographic Atrophy
- Interventions
- Lampalizumab, Sham
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
- Interventions
- Ascorbic Acid, Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment
- Dietary Supplement · Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Annapolis, Maryland • Baltimore, Maryland + 3 more
- Conditions
- Non-Infectious Uveitis
- Interventions
- FAI insert, Sham injection
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Sacramento, California • Torrance, California + 13 more